Effect of Repositioning Frequency on Bilirubin Levels and Comfort in Neonates Receiving Phototherapy: A Randomized Controlled Trial.

Int J Nurs PractSep 24, 2026
Clinical ResearchPediatrics

Sevinc Akkoyun, Sibel Kücükoglu, Fatma Tas Arslan

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial assessed the impact of repositioning frequency on bilirubin levels and comfort in neonates undergoing phototherapy. Conducted in a neonatal intensive care unit, the study found no significant differences in bilirubin levels across groups. However, comfort scores were significantly higher in the control group with a mean score of 7.14 ± 0.28 compared to 10.28 ± 0.92 and 10.63 ± 0.81 in the other groups.

Key findings

  • No significant difference in bilirubin levels between repositioning groups (p > 0.05).
  • Comfort scores were significantly higher in the control group (mean 7.14 ± 0.28) compared to other groups (p < 0.001).
  • The effect of group and time on comfort scores was statistically significant (p < 0.001).

Why it matters

Understanding the effects of repositioning on bilirubin levels and comfort can guide clinicians in optimizing phototherapy protocols for neonates, potentially improving patient comfort without compromising treatment efficacy.

Source

PubMed · PMID 42775595

Published in Int J Nurs Pract. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.